Sorted By Test Name - Mayo Medical Laboratories

FFLRO
91795
FL
8641
impaired patients treated with fluconazole. Anaphylaxis, seizures, toxic epidermal necrosis, vomiting, and
diarrhea also may occur.(2)
Useful For: Monitoring fluconazole therapy to guide dose adjustment and ensure adequate coverage
while avoiding high concentrations associated with toxicity, especially in patients who have severely
compromised renal function, for those who are undergoing dialysis, or for those where absorption may be
impacted Routine drug monitoring is not indicated in most patients
Interpretation: Serum concentration of fluconazole correlates with dose (typically 0.1-0.6 gm
administered every 24 hours): -A 0.2 gm dose produces a peak serum concentration (within 30-60 minutes
of infusion) of 4.0 to 8.0 mcg/mL in adults -A 0.4 gm dose produces a peak serum concentration of 8.0 to
16 mcg/mL Optimal peak serum concentrations vary according to indication. Peak serum concentrations
20 mcg/mL are unlikely to provide
increased efficacy and may predispose the patient to toxicity.
Reference Values:
4.0-20 mcg/mL
Clinical References: 1. Mandall GL: In Principles and Practice of Infectious Disease. Philadelphia,
Churchill Livingstone, 2000 2. Hardman JG, Limbird LE: In The Pharmacologic Basis of Therapeutics.
9th edition. New York, McGraw-Hill Book Company, 1996, p 1183
Flunitrazepam Confirmation, Serum
Reference Values:
Units: Flunitrazepam ng/mL
7-Aminoflunitrazepam ng/mL
Peak plasma Flunitrazepam concentrations in patients receiving chronic, recommended dosages: 10-20
ng/mL.
Note: Flunitrazepam is not legally marketed in the United States.
Test Performed By: Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
Fluoride, Plasma
Clinical Information: Fluoride induces bone formation by stimulating osteoblasts. Because fluorides
increase bone density, they are used in dental preparations and as an antiosteoporotic agent. However,
prolonged high exposure to fluoride produces changes in bone morphology consistent with osteomalacia,
including prolonged mineralization lag time and increased osteoid thickness. The adverse skeletal effects
of fluoride are associated with plasma fluoride >4 mcmol/L. Chronic fluorosis may produce
osteosclerosis, periostitis, calcification of ligaments and tendons, and crippling deformities. Prolonged
exposure to the fluoride-containing antifungal agent voriconazole can produce high plasma fluoride
concentrations and bone changes (periostitis).
Useful For: Assessing accidental fluoride ingestion Monitoring patients receiving sodium fluoride for
bone disease or patients receiving voriconazole therapy
Interpretation: Humans exposed to fluoride-treated water typically have plasma fluoride in the range
of 1 to 4 mcmol/L. Those who are not drinking fluoride-treated water have plasma fluoride 4 mcmol/L indicate excessive exposure and are associated with periostitis.
Reference Values:
0.0-4.0 mcmol/L
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 754